Global Health Limited (Medanta) has announced the strategic acquisition of a 79-bedded cancer care hospital in Indore. The transaction, valued at Rs. 30 crores, involves a Business Transfer Agreement that will see the facility integrated into the existing Medanta network. Located just 500 meters from the company’s current Indore facility, this expansion aims to strengthen oncology services and enhance tertiary care delivery in the region.
Strategic Acquisition in Indore
Global Health Limited, operating under the brand name Medanta, has approved a definitive agreement to acquire a 79-bedded advance super-specialty hospital currently owned and operated by the Asian Institute of Oncology Private Limited. This acquisition, approved by the Board on April 27, 2026, will see the company gain 100% control over the business undertaking.
Financial and Operational Highlights
The total consideration for the transaction is Rs. 30 crores, which will be funded through a strategic combination of internal accruals and debt financing. The target hospital reported a turnover of Rs. 19.9 million for the financial year 2024-25. As of March 31, 2026, Medanta’s total capacity stood at 3,579 beds, and this addition is expected to be completed well before the long-stop date of September 30, 2026.
Rationale and Future Impact
This acquisition is highly strategic for Medanta, as the facility is located a mere 500 meters from their existing Indore hospital. By integrating this purpose-built cancer care unit, Medanta aims to achieve seamless operational synergies, fill existing gaps in specialized oncology services, and further strengthen its portfolio of tertiary and quaternary care offerings in the region.
Source: BSE
